Ultrasound-triggered release of miR-199a-3p from liposome nanobubbles for enhanced hepatocellular carcinoma treatment

References

• Redd Bowman KE, Lu P, Vander Mause ER, et al. Advances in delivery vectors for gene therapy in liver cancer. Ther Deliv. 2020;11(1):833–850. doi: 10.4155/tde-2019-0076.
   PubMed Web of Science ®Google Scholar
• Hernandez-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. World J Gastroenterol. 2006;12(38):6085–6097. doi: 10.3748/wjg.v12.i38.6085.
   PubMed Web of Science ®Google Scholar
• Kamimura K, Yokoo T, Abe H, et al. Gene therapy for liver cancers: current status from basic to clinics. Cancers. 2019;11(12):1865. doi: 10.3390/cancers11121865.
   PubMed Web of Science ®Google Scholar
• Bartel D. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233. doi: 10.1016/j.cell.2009.01.002.
   PubMed Web of Science ®Google Scholar
• Gu S, Chan W-Y. Flexible and versatile as a chameleon—sophisticated functions of microRNA-199a. Int J Mol Sci. 2012;13(7):8449–8466. doi: 10.3390/ijms13078449.
   PubMed Web of Science ®Google Scholar
• Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011;19(2):232–243. doi: 10.1016/j.ccr.2011.01.001.
   PubMed Web of Science ®Google Scholar
• Chen B, Zhang D, Kuai J, et al. Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells. Tumour Biol. 2017;39(6):1010428317715155. doi: 10.1177/1010428317715155.
   Google Scholar
• Fan X, Zhou S, Zheng M, et al. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM). Biomed Pharmacother. 2017;88:507–514. doi: 10.1016/j.biopha.2017.01.058.
   PubMed Web of Science ®Google Scholar
• Suzuki HI, Katsura A, Matsuyama H, et al. MicroRNA regulons in tumor microenvironment. Oncogene. 2015;34(24):3085–3094. doi: 10.1038/onc.2014.254.
   PubMed Web of Science ®Google Scholar
• Paladini L, Fabris L, Bottai G, et al. Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res. 2016;35:1–19.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou Y, Zhang L, et al. microRNA-199a-3p inhibits hepatic apoptosis and hepatocarcinogenesis by targeting PDCD4. Oncogenesis. 2020;9(10):95. doi: 10.1038/s41389-020-00282-y.
   PubMed Web of Science ®Google Scholar
• Callegari E, Guerriero P, Bassi C, et al. miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models. Mol Ther Nucleic Acids. 2022;29:538–549. doi: 10.1016/j.omtn.2022.07.015.
   PubMedGoogle Scholar
• Chen Z-Y, Yang F, Lin Y, et al. New development and application of ultrasound targeted microbubble destruction in gene therapy and drug delivery. Curr Gene Ther. 2013;13(4):250–274. doi: 10.2174/15665232113139990003.
   PubMed Web of Science ®Google Scholar
• Mayer CR, Geis NA, Katus HA, et al. Ultrasound targeted microbubble destruction for drug and gene delivery. Expert Opin Drug Deliv. 2008;5(10):1121–1138. doi: 10.1517/17425247.5.10.1121.
   PubMed Web of Science ®Google Scholar
• Carson AR, McTiernan CF, Lavery L, et al. Gene therapy of carcinoma using ultrasound-targeted microbubble destruction. Ultrasound Med Biol. 2011;37(3):393–402. doi: 10.1016/j.ultrasmedbio.2010.11.011.
   PubMed Web of Science ®Google Scholar
• Shin Low S, Nong Lim C, Yew M, et al. Recent ultrasound advancements for the manipulation of nanobiomaterials and nanoformulations for drug delivery. Ultrason Sonochem. 2021;80:105805. doi: 10.1016/j.ultsonch.2021.105805.
   PubMed Web of Science ®Google Scholar
• Aw MS, Paniwnyk L, Losic D. The progressive role of acoustic cavitation for non-invasive therapies, contrast imaging and blood-tumor permeability enhancement. Expert Opin Drug Deliv. 2016;13(10):1383–1396. doi: 10.1080/17425247.2016.1192123.
   PubMed Web of Science ®Google Scholar
• Juffermans LJM, Dijkmans PA, Musters RJP, et al. Transient permeabilization of cell membranes by ultrasound-exposed microbubbles is related to formation of hydrogen peroxide. Am J Physiol Heart Circ Physiol. 2006;291(4):H1595–H1601. doi: 10.1152/ajpheart.01120.2005.
   PubMed Web of Science ®Google Scholar
• Chen S, Ding J-h, Bekeredjian R, et al. Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc Natl Acad Sci U S A. 2006;103(22):8469–8474. doi: 10.1073/pnas.0602921103.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang Y, Shu H, et al. Highlights in ultrasound-targeted microbubble destruction-mediated gene/drug delivery strategy for treatment of malignancies. Int J Pharm. 2022;613:121412. doi: 10.1016/j.ijpharm.2021.121412.
   PubMedGoogle Scholar
• Hernot S, Klibanov A. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1153–1166. doi: 10.1016/j.addr.2008.03.005.
   PubMed Web of Science ®Google Scholar
• Luk BT, Zhang L. Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces. 2014;6(24):21859–21873.
   PubMed Web of Science ®Google Scholar
• Li HL, Zheng XZ, Wang HP, et al. Ultrasound-targeted microbubble destruction enhances AAV-mediated gene transfection in human RPE cells in vitro and rat retina in vivo. Gene Ther. 2009;16(9):1146–1153. doi: 10.1038/gt.2009.84.
   PubMed Web of Science ®Google Scholar
• Deng Q, Chen J-L, Zhou Q, et al. Ultrasound microbubbles combined with the NFκB binding motif increase transfection efficiency by enhancing the cytoplasmic and nuclear import of plasmid DNA. Mol Med Rep. 2013;8(5):1439–1445. doi: 10.3892/mmr.2013.1672.
   PubMed Web of Science ®Google Scholar
• Schutt EG, Klein DH, Mattrey RM, et al. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: the key role of perfluorochemicals. Angew Chem Int Ed Engl. 2003;42(28):3218–3235. doi: 10.1002/anie.200200550.
   PubMed Web of Science ®Google Scholar
• Rix A, Curaj A, Liehn E, et al. Ultrasound microbubbles for diagnosis and treatment of cardiovascular diseases. Semin Thromb Hemost. 2020;46(5):545–552. doi: 10.1055/s-0039-1688492.
   PubMedGoogle Scholar
• Amate M, Goldgewicht J, Sellamuthu B, et al. The effect of ultrasound pulse length on microbubble cavitation induced antibody accumulation and distribution in a mouse model of breast cancer. Nanotheranostics. 2020;4(4):256–269. doi: 10.7150/ntno.46892.
   PubMedGoogle Scholar
• Guo X-M, Chen J-L, Zeng B-H, et al. Ultrasound-mediated delivery of RGD-conjugated nanobubbles loaded with fingolimod and superparamagnetic iron oxide nanoparticles: targeting hepatocellular carcinoma and enhancing magnetic resonance imaging. RSC Adv. 2020;10(64):39348–39358. doi: 10.1039/d0ra06415g.
   PubMed Web of Science ®Google Scholar
• Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem. 2000;275(29):21785–21788. doi: 10.1074/jbc.R000003200.
   PubMed Web of Science ®Google Scholar
• Asati S, Pandey V, Soni V. RGD peptide as a targeting moiety for theranostic purpose: an update study. Int J Pept Res Ther. 2019;25(1):49–65. doi: 10.1007/s10989-018-9728-3.
   Web of Science ®Google Scholar
• Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002;62(18):5139–5143.
   PubMed Web of Science ®Google Scholar
• Subhan MA, Yalamarty SSK, Filipczak N, et al. Recent advances in tumor targeting via EPR effect for cancer treatment. J Pers Med. 2021;11(6):571.
   PubMed Web of Science ®Google Scholar
• Wang Z, Ting Z, Li Y, et al. microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncol Lett. 2013;6(3):789–794. doi: 10.3892/ol.2013.1448.
   PubMed Web of Science ®Google Scholar